Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 19.0-999.0,  Chronic Heart Failure New York Heart Association Class IIIB or IV heart failure despite optimal medical therapy, including ACE inhibitors, beta blockers, IV diuretics and pressors 2. Left Ventricular Ejection Fraction < 40%. 3. Patient is not a candidate for conventional catheter-based or surgical intervention such as valve intervention or coronary artery bypass surgery. 4. Patient is not currently a candidate for heart transplantation or placement of a left ventricular assist device (LVAD) as bridge to heart transplantation due to co-morbidities. Patients may become a candidate for these options if they have improvement on the device due to improved cardiac output. 5. Patients have exhausted all approved surgical and medical therapies as determined by a heart failure cardiologist and a surgeon with expertise in heart failure. 6. Patient has been evaluated by a multi-disciplinary research team and felt to be a suitable candidate for a research study. The final decision regarding the patient's candidacy for research will remain with the attending cardiologist and heart surgeon. 7. Improved hemodynamics on device support will allow for potential for physical rehabilitation. 8. Signed Informed Consent, or oral informed consent with written confirmation by uninvolved third party 9. Age of subject at least 19 years  High likelihood of death during the current hospitalization (as judged by the attending physician) and condition other than heart failure that would limit survival to less than two years. 2. Require mechanical ventilation. 3. Failure to wean from IABP, Impella, ECMO or other mode of circulatory support. 4. Complex arrhythmias that negatively impact the effectiveness of counter pulsation. 5. Dependency on high dose inotropes. 6. Cerebrovascular accident or TIA within the previous 3 months. 7. Contraindication to anticoagulation medication such as Heparin, Coumadin, Aspirin and Plavix. 8. Presence of hypercoaguable state or history of idiopathic venous or arterial thrombosis. 9. Severe calcification in the target vessel that will preclude insertion of the Symphony device. 10. Moderate to severe aortic insufficiency (2+ or more). 11. Ongoing systemic infection defined as two of the following WBC > 12,500 positive blood culture fever 12. Abnormal pre-albumin (< 13mg/dL), or albumin (< 3.0 mg/dl) 13. A cardiac rhythm that cannot be used to trigger the CPD (sinus rhythm, ventricular or atrial pacing, A-V pacing). 14. Abnormal bilateral carotid Doppler or CT exam define as > 50% stenosis. 15. Subclavian artery internal diameter of < 7 mm on Doppler study or CT exam. 16. Ability to ambulate < 200 metres on a 6 minute walk test. 17. Any aortic aneurysmal disease. 18. Active documented HIT. 19. Presence of mechanical heart valve. 20. Moderate to severe RV failure. 21. Severe tricuspid regurgitation. 22. History of major psychiatric illness. 23. End-organ dysfunction including renal failure defined as serum Cr > 2.5 mg/dl liver dysfunction defined as bilirubin 2X normal, or elevated INR with no anticoagulation respiratory failure defined as FEV1 < 50% predicted. 24. Chest X-ray to rule out pulmonary pathology that increases the risk of need for treatment prior to device implant. 25. BMI > 40 kg/ m2. 26. Active participation in another clinical trial that may interfere with this trial